Thomas Jaki

Best Publications

• Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

  Yeming Wang;Yeming Wang;Dingyu Zhang;Guanhua Du;Ronghui Du

  3853
  Citations

• Adaptive designs in clinical trials: why use them, and how to run and report them

  Philip Pallmann;Alun W. Bedding;Babak Choodari-Oskooei;Munyaradzi Dimairo

  770
  Citations

• Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

  P Horby;W S Lim;J Emberson;M Mafham

  674
  Citations

• Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

  Peter W Horby;Marion Mafham;Jennifer L Bell;Louise Linsell

  616
  Citations

• Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

  Peter Horby;Wei Shen Lim;Jonathan Emberson;Marion Mafham

  565
  Citations

• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

  P Horby;G Pessoa-Amorim;L Peto

  258
  Citations

• Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.

  P Horby;M Mafham;L Linsell;J L Bell

  251
  Citations

• A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection

  Dominic Magirr;Thomas Jaki;John Whitehead

  180
  Citations

• The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

  Munyaradzi Dimairo;Philip Pallmann;James Wason;James Wason;Susan Todd

  142
  Citations

• A review of statistical updating methods for clinical prediction models

  Ting-Li Su;Thomas Friedrich Jaki;Graeme Hickey;Iain Buchan

  140
  Citations

• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

  P Horby;M Mafham;L Peto

  126
  Citations

• Probabilistic relabelling strategies for the label switching problem in Bayesian mixture models

  M. Sperrin;T. Jaki;E. Wit

  126
  Citations

• Optimal design of multi-arm multi-stage trials

  James M. S. Wason;Thomas Jaki

  126
  Citations

• Some recommendations for multi-arm multi-stage trials

  James Wason;Dominic Magirr;Martin Law;Thomas Jaki

  119
  Citations

• Assessing differential effects: applying regression mixture models to identify variations in the influence of family resources on academic achievement.

  M. Lee Van Horn;Thomas Jaki;Katherine Masyn;Sharon Landesman Ramey

  115
  Citations

• Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

  Saye H Khoo;Richard Fitzgerald;Thomas Fletcher;Thomas Fletcher;Sean Ewings

  107
  Citations

• How to design a dose-finding study using the continual reassessment method

  Graham M. Wheeler;Adrian P. Mander;Alun Bedding;Kristian Brock

  99
  Citations

• Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

  Peter W Horby;Lise Estcourt;Leon Peto

  92
  Citations

• Estimation of pharmacokinetic parameters with the R package PK.

  Thomas Jaki;Martin J. Wolfsegger

  88
  Citations

• Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.

  Yeming Wang;Fei Zhou;Dingyu Zhang;Jianping Zhao

  81
  Citations